Premium
Estimation of binding rate constants using a simultaneous mixed‐effects method: application to monoamine transporter reuptake inhibitor reboxetine
Author(s) -
Benson Neil,
Snelder Nelleke,
Ploeger Bart,
Napier Carolyn,
Sale Harriet,
JM Birdsall Nigel,
Butt Richard P,
van der Graaf Piet H
Publication year - 2010
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2010.00719.x
Subject(s) - reboxetine , enantiomer , chemistry , reuptake inhibitor , pharmacology , stereochemistry , biochemistry , serotonin , medicine , receptor
Background and purpose: Reboxetine is a clinically used antidepressant and is a racemic mixture of two enantiomers, SS‐ and RR‐reboxetine. The aim of the work described in this manuscript was to determine the kinetics of binding of the RR‐ and SS‐reboxetine to the human noradrenaline transporter (hNET). Experimental approach: We have applied a simultaneous mixed‐effects method to the analysis of the transient kinetics of binding of SS‐, RR‐ and racemic reboxetine to hNET. This method allowed simultaneous modelling of multiple datasets, taking into account inter‐experiment variability, thereby facilitating robust parameter estimation and minimizing the assumptions made. Key results: The mixed‐effects method proved simple and robust. SS‐reboxetine bound to hNET according to a one‐step binding model with the SS‐enantiomer having 130‐fold higher steady state affinity than the RR‐enantiomer ( K d = 0.076 ± 0.009 nM vs. 9.7 ± 0.8 nM respectively). The k on for SS‐reboxetine was c. 1.4 × 10 5 M −1 ·s −1 and k off 1.05 × 10 −5 s −1 ( t 1/2 ∼18 h). The k on for RR‐reboxetine was c. 4.3 × 10 5 M −1 ·s −1 and k off 4.2 × 10 −3 s −1 ( t 1/2 ∼3 min). The racemate behaved as expected for an equimolar mixture of RR‐ and SS‐reboxetine, assuming mutually exclusive binding. Conclusions and implications: These data will be useful for the interpretation of the behaviour of reboxetine and its enantiomers in man and the method used could be applied to other candidate drugs.